쿼드메디슨

464490KOSDAQSector: Pharma & Biotech

₩5,620▼ 5.39%Market cap ₩64.5BAs of Jul 21, 2026 close · updated once daily

Grade D39.4 ptsTop 72% of 2,523 stocks

Financial strength

41.3

Growth momentum

44.6

Price attractiveness

33.5

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Financial strength

41.3

How much debt does it carry relative to equity?

Debt-to-equity ratio

66.2%

✗ Below median · Top 62% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

286.9%

✓ Above median · Top 35.2% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

-59.7%

✗ Below median · Top 69.3% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

-22.3%

✗ Below median · Top 68.5% in sector

Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

Growth momentum

44.6

How much did revenue grow in a year?

Revenue growth (YoY)

15.0%

✓ Above median · Top 29.9% in sector

Sector median 6.4%

Did core profits grow in a year?

Operating income change (YoY)

-43.5%

✗ Below median · Top 81% in sector

Sector median 3.6%

Source filing: annual report (consolidated) — view original ↗

Price attractiveness

33.5

Is the price expensive relative to earnings?

P/E (price-to-earnings)

Loss-making (P/E not computable)

✗ Below median · Top 73% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

2.10x

✗ Below median · Top 60% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15